Foundation Medicine (FMI) Tops Q1 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights
May 3, 2016 4:04 PM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its first quarter ended March 31, 2016. Highlights for the quarter included:
Achieved first quarter revenue of $30.4 million, 57% year-over-year growth; Reported 8,985 clinical tests in the first quarter, 14% year-over-year growth; Grew the FoundationCORE molecular information knowledgebase, now approaching 80,000 patient cases;... MoreFoundation Medicine Announces Commercial Launch of Liquid Biopsy Assay, FoundationACT™
May 3, 2016 4:02 PM EDT-- Blood-based Genomic Profiling Assay Provides New Option for Cancer Patients Who Are Not Candidates for Tissue Biopsy --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today announced the launch of FoundationACT (Assay for Circulating Tumor DNA), an analytically validated and accurate blood-based circulating tumor DNA (ctDNA) assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available. By analyzing circulating tumor DNA isolated from a patients blood, FoundationACT can identify clinically... More
